In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...
MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...
On Monday, 08 September 2025, Lexicon Pharmaceuticals (NASDAQ:LXRX) presented at the H.C. Wainwright 27th Annual Global Investment Conference, providing a strategic overview of its key programs. The ...
Okay. Welcome back, everyone, for those listening in the room and on the webcast. I'm Yigal Nochomovitz, biotech analyst here at Citi. And this is the second day of our biopharma back-to-school ...
MADRID -- Mavacamten (Camzyos) failed to replicate its previous successes in hypertrophic cardiomyopathy (HCM) when applied to a population with symptomatic, nonobstructive disease, the phase III ...
Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...
Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten did not improve outcomes vs. placebo at 48 weeks in patients with nonobstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback